387 related articles for article (PubMed ID: 24583420)
21. Graves' Ophthalmopathy in a Paediatric Population.
Sadeghi Y; Obéric A; Theintz G; Hamédani M
Klin Monbl Augenheilkd; 2017 Apr; 234(4):591-594. PubMed ID: 28329893
[No Abstract] [Full Text] [Related]
22. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
[TBL] [Abstract][Full Text] [Related]
23. Hyperthyroidism in Patients with Graves' Ophthalmopathy, and Thyroidal, Skeletal and Eye Muscle Specific Type 2 Deiodinase Enzyme Activities.
Molnár I; Szentmiklósi JA; Somogyiné-Vári É
Exp Clin Endocrinol Diabetes; 2017 Sep; 125(8):514-521. PubMed ID: 28750432
[TBL] [Abstract][Full Text] [Related]
24. Thyroid Eye Disease: Epidemiology, Natural History, and Risk Factors.
Bartalena L; Gallo D; Tanda ML; Kahaly GJ
Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S2-S8. PubMed ID: 38054980
[TBL] [Abstract][Full Text] [Related]
25. [Graves' ophthalmopathy from the internist's perspective].
Laubner K; Weber WA; Seufert J
Ophthalmologe; 2011 May; 108(5):410-6. PubMed ID: 21590351
[TBL] [Abstract][Full Text] [Related]
26. Influence of biological sex, age and smoking on Graves' orbitopathy - a ten-year tertiary referral center analysis.
Oeverhaus M; Winkler L; Stähr K; Daser A; Bechrakis N; Stöhr M; Chen Y; Eckstein A
Front Endocrinol (Lausanne); 2023; 14():1160172. PubMed ID: 37082130
[TBL] [Abstract][Full Text] [Related]
27. The influence of prior hyperthyroidism on euthyroid graves' ophthalmopathy.
Termote K; Decallonne B; Mombaerts I
J Ophthalmol; 2014; 2014():426898. PubMed ID: 25045529
[TBL] [Abstract][Full Text] [Related]
28. Post-radioiodine De Novo Onset Graves' Ophthalmopathy: Case Reports and a Review of the Literature.
Batra R; Krishnasamy SK; Buch H; Sandramouli S
Semin Ophthalmol; 2015 May; 30(3):227-31. PubMed ID: 24409943
[TBL] [Abstract][Full Text] [Related]
29. Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.
Khamisi S; Anders Karlsson F; Ljunggren Ö; Thulin M; Larsson A
Cytokine; 2023 Sep; 169():156269. PubMed ID: 37307688
[TBL] [Abstract][Full Text] [Related]
30. Clinical update: treatment of hyperthyroidism in Graves' ophthalmopathy.
Azzam I; Tordjman K
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():193-7. PubMed ID: 20467362
[TBL] [Abstract][Full Text] [Related]
31. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Kubota S; Swanson J; Wengrowicz S; Cochran B; Ackrell BA; Salvi M; Bellastella A; Bizzarro A; Sinisi AA; Wall JR
J Clin Endocrinol Metab; 1999 Apr; 84(4):1255-62. PubMed ID: 10199764
[TBL] [Abstract][Full Text] [Related]
32. Treatment options for Graves' orbitopathy.
Marcocci C; Altea MA; Leo M
Expert Opin Pharmacother; 2012 Apr; 13(6):795-806. PubMed ID: 22404364
[TBL] [Abstract][Full Text] [Related]
33. Graves' ophthalmopathy and atrophic thyroiditis: a case report.
Tamagno G; De Carlo E; Betterle C; Murialdo G
J Endocrinol Invest; 2004 Feb; 27(2):163-6. PubMed ID: 15129812
[TBL] [Abstract][Full Text] [Related]
34. Treating the thyroid in the presence of Graves' ophthalmopathy.
Hegedüs L; Bonnema SJ; Smith TJ; Brix TH
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):313-24. PubMed ID: 22632368
[TBL] [Abstract][Full Text] [Related]
35. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR
J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210
[TBL] [Abstract][Full Text] [Related]
36. The risk factors for Graves' ophthalmopathy.
Cao J; Su Y; Chen Z; Ma C; Xiong W
Graefes Arch Clin Exp Ophthalmol; 2022 Apr; 260(4):1043-1054. PubMed ID: 34787691
[TBL] [Abstract][Full Text] [Related]
37. Increased TRAb and/or low anti-TPO titers at diagnosis of graves' disease are associated with an increased risk of developing ophthalmopathy after onset.
Lantz M; Planck T; Asman P; Hallengren B
Exp Clin Endocrinol Diabetes; 2014 Feb; 122(2):113-7. PubMed ID: 24554511
[TBL] [Abstract][Full Text] [Related]
38. Risk Factors for Graves' Orbitopathy; the Australian Thyroid-Associated Orbitopathy Research (ATOR) Study.
Khong JJ; Finch S; De Silva C; Rylander S; Craig JE; Selva D; Ebeling PR
J Clin Endocrinol Metab; 2016 Jul; 101(7):2711-20. PubMed ID: 27055083
[TBL] [Abstract][Full Text] [Related]
39. The tale of radioiodine and Graves' orbitopathy.
Ponto KA; Zang S; Kahaly GJ
Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895
[TBL] [Abstract][Full Text] [Related]
40. Ethnic differences in the clinical presentation of Graves' ophthalmopathy.
Chng CL; Seah LL; Khoo DH
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):249-58. PubMed ID: 22632362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
